Novo Nordisk is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples with supply constraints and competition from Eli Lilly & Co. CEO Lars Fruergaard Jorgensen says the company will continue to ramp up supply of its popular weight-loss drug "gradually." He spoke with Bloomberg's Katie Greifeld and Romaine Bostick.

Charles Schwab Chief Fixed Income Strategist Kathy Jones Talks Treasuries and Fed Interest Rates
07:39

President and CEO of Stew Leonard's, Steward Leonard Jr., Talks Consumer Spending and War Impact
06:06

Democratic Senator Gary Peters of Michigan Talks Pentagon Funding, Rising Gas Prices
11:20